Glenza 160mg is a prescription medication that contains 160mg of Enzalutamide, a non-steroidal androgen receptor inhibitor. It is available in capsule form and is used to treat metastatic castration-resistant prostate cancer (mCRPC).
Composition:
Glenza 160mg contains 160mg of Enzalutamide, a white or off-white powder.
Mechanism of Action:
Enzalutamide works by:
- Binding to the androgen receptor, preventing the binding of androgens such as testosterone
- Reducing the growth and proliferation of cancer cells
- Inducing apoptosis (cell death) in cancer cells
Indication:
Glenza 160mg is indicated for the treatment of:
- Metastatic castration-resistant prostate cancer (mCRPC)
Dosage:
The recommended dosage of Glenza 160mg is:
- 160mg once daily
Side Effects:
Common side effects of Glenza 160mg may include:
- Fatigue
- Back pain
- Arthritis
- Hot flashes
- Headache
- Increased risk of falls
- Cough
- Increased blood pressure
- Weight loss
Recommendation:
Glenza 160mg should only be used under the guidance of a healthcare provider. Patients receiving Glenza 160mg treatment should be closely monitored for side effects and potential complications.
Important Note:
- Glenza 160mg is a potent medication that can cause serious side effects, including increased risk of falls, fractures, and seizures. Patients should be closely monitored for these side effects.
- Patients should not take Glenza 160mg without consulting a healthcare provider.
- Patients should not consume alcohol while taking Glenza 160mg, as it can increase the risk of side effects.
- Patients should not take Glenza 160mg without proper medical supervision.
Special Precautions:
- Patients with history of seizures or seizure disorder should be closely monitored while taking Glenza 160mg.
- Patients with history of falls or bone fractures should be closely monitored while taking Glenza 160mg.
- Patients with cardiovascular disease or risk factors should be closely monitored while taking Glenza 160mg.
- Patients with history of depression or suicidal thoughts should be closely monitored while taking Glenza 160mg.
Warnings:
- Patients with severe liver disease should not take Glenza 160mg.
- Patients with severe kidney disease should not take Glenza 160mg.
- Patients with a history of stroke or transient ischemic attack (TIA) should not take Glenza 160mg.
It is important to note that the dosage and administration of Glenza 160mg may vary depending on the patient’s individual needs and medical history. It is recommended that patients consult their healthcare provider before taking this medication.
Reviews
There are no reviews yet.